Guided Therapeutics (GTHP) Stock Price

Guided Therapeutics Price

OTC·CLOSED
0.19
​
Market closed

Revenue has compounded at 1.3% per year over the past 19 years to 767,000.00 USD. Guided Therapeutics's net margin stands at -416.7%, up from -2,555.6% several years earlier.

Guided Therapeutics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics business model & stock analysis

Guided Therapeutics Inc, with ticker GTHP and ISIN US40171F5017, is a health care company headquartered in Norcross, Georgia. The company has 6 employees and went public on July 1, 1997. Guided Therapeutics focuses on developing medical devices, particularly utilizing biophotonic technology for cancer detection. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device designed to detect cervical cancer and precancers. The LuViva device scans the cervix with light and analyzes the reflected and fluorescent light to provide results at the point of care. It serves as an alternative to conventional cervical cancer screening methods, targeting two main applications: as a screening tool and as a triage method for traditional screening processes. The company develops prototypes and conducts limited clinical studies using its biophotonic technology, which is central to its approach for detecting esophageal cancer. Guided Therapeutics operates within the health care sector and industry, with its website at https://www.guidedinc.com/. The company's current operational focus is on the development and marketing of the LuViva device, though it has also explored applications in esophageal cancer detection through biophotonic technology. Guided Therapeutics has a small workforce of six full-time employees, reflecting its current scale of operations.

Frequently asked questions about Guided Therapeutics

Converted at the current exchange rate, the Guided Therapeutics share trades at 0.17 EUR (0.19 USD).

The revenue cannot currently be calculated for Guided Therapeutics.

The profit cannot currently be calculated for Guided Therapeutics.

The P/E ratio cannot be calculated for Guided Therapeutics at the moment.

The P/S cannot be calculated for Guided Therapeutics currently.

The Eulerpool Quality Score for Guided Therapeutics is 3/10.

The ISIN of Guided Therapeutics is US40171F5017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Guided Therapeutics is GTHP. The ticker symbol is used to trade Guided Therapeutics shares on the stock exchange.

Fair ValueTerminal
0.16 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
127,833.33 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jul 1, 1997
ISIN
US40171F5017
Cusip
40171F501
Market capitalization
10.89 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
53.60 %
Last updated Oct 18, 2026, 8:21 PM

Guided Therapeutics Peer Group

Guided Therapeutics Ticker

OTC · GTHPOTC · GTHP

Guided Therapeutics FIGI

GTHP:US · BBG000BQNW12GTHP:PQ · BBG000BQP341GTHP:UV · BBG000BQP3M1GTHPGBP:X2 · BBG00JWNYZC4GTHPGBP:XB · BBG00JWNYZD3GTHPGBP:XH · BBG00JWNYZG0GTHPGBP:XF · BBG00JWNYZJ7GTHPGBP:XE · BBG00JWNYZL4GTHPGBP:XJ · BBG00JWNYZM3GTHPGBP:XL · BBG00JWNYZN2GTHPGBP:XG · BBG00JWNYZP0GTHPGBP:XO · BBG00JWNYZQ9